Determination of the Intrinsic Efficacies of β2 -adrenergic Agonists  by Barber, Roger
Determination of the Intrinsic
Efficacies of2 -adrenergic Agonists
Roger Barber1
ABSTRACT
β-adrenergic agonists have been traditionally classified as strong or weak. Attempts to express their effective-
ness in quantitative terms has led to the concepts of potency, which designates the concentration range over
which the agonist becomes effective, and the intrinsic activity, which designates the maximal effect produced
by agonist at saturating concentrations. In the present review we describe developments in which the molecular
effects of the common β-adrenergic agonists on their cognate receptors can be related to their effectiveness.
This approach is based on the activationinactivation cycle of G proteins. It has been formalized so that the ef-
fectiveness (that is the efficacy) of each individual β-adrenergic agonist can be expressed as a single numerical
value. The agonists may, therefore, be listed is order of efficacy. For the β-adrenergic agonists for which there
is accurate data the order is : epinephrine > fenoterolprocaterol > albuterolzinterolterbutaline > dobu-
tamine > tulobuterol > ephedrine. The formal model of β-adrenergic agonism also allows a novel approach to
the question of agonist specificity and a more rational appraisal of which drugs might be most useful for particu-
lar purposes．
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INTRODUCTION
This review concentrates on assessing the relative
abilities of the β-adrenergic agonists to activate
adenylyl cyclase. A priori the ideal approach to meas-
uring those abilities should be able to order the ago-
nists from the strongest to the weakest and be usable
in all tissues. It should be quantitative, rather than
merely descriptive at the verbal level. It should be as-
sociated with a quantitative system of measuring tis-
sue response which allows for prediction of experi-
mental results as well as mere description of experi-
mental results already obtained. In this review we de-
scribe how beta-adrenergic agonist efficacy has been
related to the ability of agonist to promote GTPGDP
exchange in the Cassel-Selinger 1 cycle of adenylyl
cyclase activation. The relationship between this abil-
ity and the traditional measurements of agonist effec-
tiveness (potency and intrinsic activity) is straightfor-
ward. Following Furchgott2 we will define this ability
as efficacy. In subsequent sections we show how the
relationship was developed and show how it may be
measured and used in practice.
CLASSICAL DESCRIPTION OF TISSUE RE-
SPONSE TO A DRUG
Figure 1 illustrates the classic descriptors for a dose-
response to a drug . The effect measured is for
adenylyl cyclase activity for a preparation of Human
Embryonic Kidney cells (HEK293 cells) transfected
with additional human beta-adrenergic receptor. The
measurement of adenylyl cyclase activities in mem-
brane preparations from these cells has been de-
scribed in detail.3 It is obvious that the maximal re-
sponse at saturating epinephrine concentrations is
greater than that for zinterol, while the EC50 for zin-
terol is less that that of epinephrine. In other words,
the epinephrine has a greater “intrinsic activity” than
the zinterol, but the zinterol is more “potent” than the
epinephrine. In the classical approach to the descrip-
tion of drug response, both potency and intrinsic ac-
tivity are necessary in this approach to define the re-
lationship between response and drug concentration.
There is no obvious relationship between the two pa-
rameters and it is not clear which should be consid-
ered the “strongest” agonist.4 Epinephrine produces
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Fig. 1 The adenylyl cyclase activity in membranes pre-
pared form HEK293 cels transfected with additional β-adre-
nergic receptor in response to epinephrine and zinterol. The 
EC50 and Vmax for both agonists are indicated by arows.
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Fig. 2 A replot of the data shown in Figure 1, but with the 
agonist concentrations normalized to their dissociation con-
stants on the β-adrenergic receptors. With this type of plot 
positions on the abscissa corespond to equal receptor oc-
cupancy for both agonists. 
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greater effects at saturating concentrations , but at
any equal concentration of the two drugs below 10
nM zinterol causes a greater effect.
This problem of which drug is inherently stronger
is alleviated to some extent by comparing the drugs
at equal occupancies of the receptors . This is
achieved by plotting the effects of the drug against its
concentration divided by its dissociation constant
(Kd). Figure 2, where the data from Figure 1 are plot-
ted in this manner, is an example of such a plot. In
this type of plot the value 0 on the x-axis corresponds
to a drug concentration to Kd ratio ([concentration]
Kd ) of 1 and, therefore, to 50% occupancy of the re-
ceptors by the drug . The EC50 for zinterol occurs
when [concentration]Kd is about 0.1 and the EC50
for epinephrine occurs when [concentration]Kd is
about 0.02. A plot of this type makes it clear that epi-
nephrine gives more stimulation at all receptor occu-
pancies and should presumably be described as a
“stronger” agonist than zinterol. It is still not clear,
however, even from a plot of this type how their rela-
tive strengths should be measured. Figure 3 extends
the data in Figure 2 to many more agonists measured
with the same membrane preparation. It may be seen
(with one small exception) that the curves do not
cross. That is, in comparing any two agonists , the
stronger agonist is stronger at all fractions of recep-
tor occupancy. The exception in these data applies to
procaterol and fenoterol. At low receptor occupancies
fenoterol gives a greater response at higher concen-
trations it is procaterol with the greater response .
This feature will be discussed later once the rational
approach to measurement of agonist efficacy has
been described . The formal , empirical equation
which relates agonist concentration, intrinsic activity
(Vmax), potency (EC50), dissociation constant (Kd )
and response (v) is：
USING THE CASSEL-SELINGER CYCLE OF
G PROTEIN ACTIVATION TO A RATIONAL
DEFINITION OF EFFICACIES
Beta-adrenergic agonists work by binding to their
cognate receptors and in combination with them cata-
lyzing the exchange of GTP for GDP on Gs. Diagram-
matically this is shown in Figure 4. 1 It has been
shown by Whaley et al.5,6 that the rate of exchange is
proportional to the number of receptors present in
the preparation or tissue and to the identity of the
drug. By noting that in the steady state of G protein
activation the rate of activation and inactivation must
be the same it was possible to derive the following
equation which relates drug response to drug con-
centration and to the rate constants for activation and
inactivation of the G protein.5,6 The equation is :
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Fig. 3 The adenylyl cyclase activity in membranes pre-
pared form HEK293 cels transfected with additional β-ad-
renergic receptor. As in Figure 2 the agonist concentrations 
are normalized to their dissociation constants so as to give 
a valid comparison at equal receptor occupancy. The data 
for epinephrine and zinterol are identical to those shown in 
Figure 2. The identity of the other agonists are indicated on 
the figure itself. The three broken lines corespond to ideal 
theoretical curves at (reading from left to right) eficiencies 
of 30, 5 and 1. 
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Fig. 4 The Cassel-Selinger cycle of adenylyl cyclase acti-
vation drawn to show the role of the rate constants used in 
the derivation of the mechanistic equation.
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where V100 is the total activity of response when all
adenylyl cyclase is active , k1 and k− 1 are ( respec-
tively) the rate constants for activation and inactiva-
tion of the adenylyl cyclase, r is the receptor concen-
tration and Kd is the dissociation for the agonist from
the receptor . The variables are v , the measured
adenylyl cyclase activity, and h, the agonist concen-
tration.
By comparison of the mechanistic equation 2 with
the empirical equation 15,6 it may be seen that :
V100, r and k−1 are properties of the membrane prepa-
ration only, and hence are not affected by the identity
of the agonist only k1(the rate constant for GTPGDP
exchange promoted by the agonistreceptor com-
plex) is dependent on the nature of the agonist. k1, r
and k−1 are all constants for any one tissue or collec-
tion of cells or membrane preparation. Therefore, the
quotient k1rk−1 is also a constant and will be written
here as “e” . It measures the ratio of the rates at
which the adenylyl cyclase is activated and inacti-
vated at saturating agonist. We define e as the effi-
cacy. Equation 2 then becomes：
This equation is identical to that derived by Furch-
gott2 using operational arguments. It was he who first
defined the agonist dependent parameter e as the effi-
cacy. Though at the time that work was published
there was no knowledge of the Cassel-Selinger1 cycle
and the derivation of his equation was not based on
any specific mechanism.
CORRESPONDENCE WITH EXPERIMENTAL
DATA
Plots of this equation for various values of the efficacy
(e) are shown in Figure 5. The similarities with the
experimental data are obvious. For each curve the
value of hKd required to give half-maximal response
( i.e. the EC50Kd ) is equal to 1(1+e) and the maxi-
mal response itself is given by e(1+e) so that inevita-
bly there is a forced relation between the maximal re-
sponse to any agonist and the occupancy of receptor
required to give half-maximal response. This relation-
ship is actually quite stringent, but it is only apparent
experimentally when responses to several agonists
are compared．
Suppose that the EC50Kd for one agonist is 0.3 and
its Vmax is 200 pmoles cAMPmg. protein .minute .
Then, since the EC50Kd is equal to 1(1+e), the effi-
cacy of the agonist in this system is calculated from
1(1+e) =0.3 and, therefore, e = 2.33. Since we know
that 200 pmoles cAMPmg. protein.minute (the Vmax )
represents e(1+e) V100 then V100 is equal to 3.33
2.33Vmax. Numerically V100 is equal to 286 pmoles
cAMPmg. protein .minute . Armed with this value
Vmax may now be calculated for any agonist whose
EC50Kd is known on an hKd plot. For an EC50Kd of
0.1, the efficacy is 9 the Vmax is 9(1+9) V100 which is
equal to 257 pmoles cAMPmg. protein.minute. If the
EC50Kd were 0.8 then the Vmax would be 50.
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Fig. 5 A series of simulations to show the  efect of incre-
asing eficacies on the dose/response to an agonist. When, 
as here, the abscissa is [concentration]/Kd, the curve repre-
senting binding as a function of increasing concentrations is 
the same for al agonists and has a value for half saturation 
of 1 (or log[concentration]/Kd = 0).
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Fig. 6 Dose responses to epinephrine and zinterol in me-
mbranes from HEK293 cels transfected with additional β-
adrenergic receptor and from S49 cels. 
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These predictions are generally borne out well in
practice . Figure 3 shows the data for the HBARH
cells plotted together with theoretical curves calcu-
lated from equation (5). The values assigned to the
efficacy for each of the theoretical curves are shown
in the legend to the figure．
FULL AND PARTIAL AGONISTS
An agonist is usually described as “full” when at satu-
rating concentrations it provokes a response which is
not exceeded by that of any other agonist, a “partial”
agonist is one that at saturating concentrations pro-
vokes a positive but lesser response . Dividing the
group of ligands which bind to any particular receptor
type into full agonists , partial agonists and antago-
nists is far too blunt. How should the agonists illus-
trated in Figure 3 be classified? Is zinterol a strong
partial agonist and tulobuterol a weak partial agonist?
Is such a classification and comparison true for all as-
say systems? How much stronger is a strong partial
agonist than a weak partial agonist? With a numerical
scale such questions are moot.7 It is to be hoped that
the introduction of a objective numerical scale will
make direct comparisons of any two agonists easy
and reliable. In looking at the data in Figure 3 it can
be calculated using the approach illustrated in equa-
tion 5 that the efficacy for zinterol is 11.4 and that for
tulobuterol is 1.7. The efficacy of the zinterol is there-
fore 11.41.7 = 6.7 times greater. A far more useful
comparison than describing one a “strong partial” ag-
onist and the other as a “weak partial” agonist．
The numerical scale is all the more necessary be-
cause while the ratio of the efficacies of agonists are
fairly constant from one assay system to another, the
extent to which they are partial or full can vary enor-
mously. Figure 6 shows the response curves for epi-
nephrine and zinterol for membranes isolated from
HEK293 HBARH cells (human embryonic kidney
cells transfected with additional β-adrenergic recep-
tors) and S49 cultured mouse lymphoma cells . In-
spection shows clearly that the maximal response for
zinterol in the HBARH cells is much closer to that for
epinephrine that is true for the same comparison with
S49 cells. In the HEK 293 HBARH cells it the maxi-
mal response was 82% of that for epinephrine and in
the S49 cells it was 53%. Using the verbal nomencla-
ture of partial and full agonism it might seem that,
relative to epinephrine, zinterol was a somewhat bet-
ter agonist in HEK293 HBARH cells than in S49. In
fact when the efficacies are calculated there is very
little difference between their ratios between the two
cell types . The number is 5.1 for the in HEK293
HBARH cells and 6.6 for the S49 cells．
These calculations emphasize the important princi-
ple that full or partial agonism depends on the assay
system and in particular on the receptor density in
the assay system. It is also only sensible to talk of full
or partial agonism in terms of a defined assay system.
The isolated statement that zinterol is a full agonist
would be more nearly true if the statement were
made in reference to the HBARH preparations de-
scribed above than for membranes isolated from S49
cells.
FINDING THE RIGHT AGONIST
In a clinical setting the aim to produce the desired re-
sponse with a minimum of deleterious side effects ,
both to the intended target system and to other organ
systems which respond to the same range of drugs as
do the target system. Some organ specificity can be
achieved by local delivery of the drugs, as when in-
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halers are used for the siting of the drug directly into
the airways. In other cases some organ specificity
may be achieved by pharmacodynamical considera-
tions where the drug is concentrated for metabolic or
physiological reasons in the desired organ system, or
where one drug is rapidly excreted while another is
not. In the present review we are concerned not with
those paths to specificity, but to the contrasts of re-
lated and alternative drugs in their interactions with
the organ system itself.
If all of the β-adrenergic agonists only promoted
the activation of Gs described in Figure 1, then there
would be no differences in their specificities and any
response which occurred as the result of treatment
with a weaker agonist could be exactly mimicked by
a lower concentration of a stronger agonist. Looking
at (say) Figure 3 at the concentrations of agonist re-
quired to activate the adenylyl cyclase to 100 pmoles
cAMPmg. protein.minute, it is clear that epineph-
rine produces this response while occupying less
than half as many sites as fenoterol. As long as the
only readout is the synthesis of cAMP then inevitably
any response level due to fenoterol can be exactly
mimicked by the appropriate concentration of epi-
nephrine.7
However, when there is more than one read-out a
response due to one agonist may be not exactly mim-
icked by any concentration of another. For instance,
epinephrine can be effectively used as a bronchodila-
tor, but it has direct effects on the heart and on the
peripheral circulation. A more specific β-adrenergic
agonist has fewer side effects on the heart and my
not, therefore, be mimicked in the totality of its re-
sponse by any concentration of epinephrine. The rea-
sons for differential specificities between agonists
which are nominally classified in the same groups are
discussed in the next section．
AGONIST SPECIFICITIES
An agonist may be less than completely specific for
one measured response in an organ system because :
1) It may combine to a variety of different receptors
which work through a variety of different message
transduction systems. Hence, activating a variety of
pathways with different or even opposing end effects.
This is a well described phenomenon. Dobutamine
(for instance) combines with and activates, dopamine
as well as β1 - and β2-adrenergic receptors. This type
of non-specificity has been well described in the past
and will not be further elaborated here．
2) The receptoragonist complex produced as the
result of binding the agonist to a single type of recep-
tor my be able to take on several different conforma-
tions and hence bring about the simultaneous activa-
tion of different pathways. It the sets of conformations
of the receptoragonist complex differ from each
other , in proportions of each produced , then the
amounts of each pathway activated will depend on the
identity of the agonist and it will not be possible to
mimic the effects of one agonist by another．
Considerations into the activation of receptors by
the binding of agonists have been simplified by sup-
posing that the receptor could exist in only two prin-
ciple conformational states.8 It was supposed that the
binding of the agonist stabilized the state which
bound to G protein and catalyzed GTPGDP ex-
change on it. If this “two-state” model were exactly
true, then all agonists working through any given re-
ceptor would have to work in exactly the same way.
Strong agonists would produce a lot of the active con-
formation and weak agonists less of it , but there
would be no difference in the type of conformation
produced and no differences in the type of down-
stream effects resulting from the binding of the vari-
ous agonists. The only differences would be in the
quantity of the effects and a high receptor occupancy
by a weak agonist could always be mimicked by a
lower occupancy of a strong agonist. Later conditions
were found where this simple model broke down .
Under those conditions it was necessary to invoke ad-
ditional conformations which were capable of interac-
tion with different G proteins.9-13
The model was therefore extended to assume that
the receptor can exist in conformations which inter-
act with (for instance) Gs, Gi or Gq. In the case of the
β2-adrenergic receptor it is supposed that the confor-
mation which interacts with Gs is formed easily since
this is the usual pathway. It is now easy to suppose
that some agonists by combining with very high af-
finities with the other conformations promote their
formation, at least to some fraction of the conforma-
tional mix. Thus it is to be expected that in order to
activate Gs to the same level, different agonists could
simultaneously activate Gi and Gq to a variety of dif-
ferent levels.
Agonists with stabilize conformations which inter-
act with Gi to a relatively large extent would be ex-
pected to give a relatively large activation of it as a
side effect.10,13 Since the inhibition of adenylyl cyc-
lase by Gi activation is largely non-competitive in na-
ture, the effect of this would be to give a low value for
the Vmax relative to what might have been expected
from the KdEC50 ratio for response.
It is now possible to see how the (relatively small)
departures from the kinetic model of Whaley et al.
are possible in terms of variations of specificity of the
agonists. It may be seen that when compared to the
values for epinephrine or procaterol the Vmax for
fenoterol response is lower than expected from its
EC50Kd ratio .As discussed above for the general
case, we conclude from this that there is not a com-
plete overlap in the second messenger systems acti-
vated by procaterol and fenoterol. It seems likely that
fenoterol in addition to activating adenylyl cyclase
also promotes activation of some of the adenylyl cyc-
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lase inhibitory systems. Similar examples using more
direct measurements on multiple systems have been
discussed by Clark and Bond.14
COMPARING AGONIST-DRIVEN PROC-
ESSES
Agonist receptor complexes catalyze processes
which change the state of other molecules within the
cell and which also change the state of the receptor it-
self (as with the promotion of internalization for in-
stance ) . The steady state of level of activation of
adenylyl cyclase in a membrane preparation depends
on the relative rates of activation and inactivation as
discussed in detail in the section on the Cassell-
Selinger1 cycles. The steady state level of desensitiza-
tion in intact cells or in tissues depends on the rela-
tive rates of the processes driving the desensitization
and the recovery from it. Even under circumstances
where the processes driving activation and desensiti-
zation depended on exactly the same conformation,
very careful consideration would have to be given in
working up the data to demonstrate that there was no
specificity between agonists in promoting the desen-
sitization process . 15,16 The calculations concerning
the comparison of two cyclic processes promoted by
the same agonistreceptor complex have been given
elsewhere. Below we illustrate with a brief calculation
the difficulty of comparing an agonist’s ability to acti-
vate and to desensitize．
The efficacies of epinephrine and zinterol taken
from the data plotted in Figure 3 are (respectively)
about 55 and 11. At saturating agonist concentration
therefore the epinephrine should induce about
55(1 + 55) × 100 = 98% of maximum possible cyclase
activity and the zinterol should induce about 11 (1 +
11) × 100 = 92% of the activity. That is indeed the
case. However, if the desensitization processes (by
phosphorylation and internalization) occur at exactly
the same proportional rates but with a relatively
much faster recovery cycle then the steady state lev-
els of desensitization will be very different. Making
the ratios of desensitization to resensitization 5.5 and
1.1 rather than 55 and 11 we get a steady state levels
of desensitization at 5.5(1 + 5.5) × 100 = 85% and 1.1
(1 + 1.1) × 100 = 52%. The ratios of the levels of activ-
ity for cyclase are therefore 9298 = 0.94 and for de-
sensitization are 5285 = 0.61. This would be true
even with a hypothesis that epinephrine and zinterol
induce exactly the same sets of conformations into
the receptor and even if the effects of any concentra-
tion of zinterol could be exactly mimicked by a some
concentration of epinephrine．
CONCLUSIONS
In summary, it may be concluded that the commonly
used β-adrenergic agonists can be assigned rationale
numerical values for their efficacies . Moreover , it
seems very likely that the relative efficacies meas-
ured for any group of agonists in one assay system
applies with good accuracy to other systems. The de-
viations from the mechanistic model which forms the
basis of the system of measurement are quite small.
When such deviations exist they may correspond to a
lack of specificity on the part of the agonist. Addition-
ally it is argued that even when agonists have the
same specificities, a comparison of the magnitudes of
all agonist-driven events may not be straightforward．
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